uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment
Company Announcements

uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment

uniQure (QURE) has shared an announcement.

uniQure N.V. has reached a significant milestone by administering the first dose in a Phase I/IIa clinical trial of AMT-191, their experimental treatment for Fabry disease. This progress may interest investors and those following biotech advancements, highlighting the company’s ongoing efforts to combat this genetic disorder.

Learn more about QURE stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskuniQure N.V. Reports Q3 2024 Progress and Financials
TheFlyuniQure reports Q3 EPS (91c), consensus ($1.01)
Jason CarruniQure N.V. (QURE) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App